Mechanisms of Atrial Pathoelectrophysiology in HCM
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorGuy's and St Thomas' NHS Foundation Trust
About this trial
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.
Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.
The information from this study may help improve future treatments for people who have both HCM and AF.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Paroxysmal or persistent atrial fibrillation
Diagnosis of hypertrophic cardiomyopathy
Patient planning to proceed to atrial fibrillation ablation following clinical consultation
Age 18-80 years
Disqualifiers
Any clinical contra-indication to ablation
Any disease limiting life expectancy to <1 year
Potential participant currently pregnant or breast feeding
Contraindication to MRI including renal dysfunction (eGFR<30ml/min)
Trial population
Patients with hypertrophic cardiomyopathy and atrial fibrillation requiring atrial fibrillation ablation.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
40 Participants
are grouped into 1 trial groupGroup A: Patients with HCM and AF
Trial outcomes
Primary outcomes
1
Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts
Time frame
At the time of the clinical ablation procedureSecondary outcomes
1
Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .
Time frame
At the time of clinical ablation procedure2
Reduction in AF inducibility in silico models following simulated ablation
Time frame
Based on measurements taken during the clinical ablation procedureSponsors and contacts
Click on the lead sponsor to view all of their trials.
Guy's and St Thomas' NHS Foundation Trust
Lead sponsor
King's College London
Collaborator
Source ClinicalTrials.gov